ArticleCureus2025
A Trend Analysis of Metastatic Lung Cancer Disparities in the United States in the Era of Lung Cancer Screening.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe introduction of low-dose chest computed tomography (LDCT) screening has shown promise in improving early detection and reducing lung cancer mortality. Nonetheless, marginalized communities have displayed limited participation in lung cancer screening, potentially diminishing its advantages within these populations. We assessed the trends in metastatic lung cancer incidence and evaluated disparities by sex, race/ethnicity, and residence type in the United States.
methodsWe analyzed data from 445,715 adults aged between 55 and 80 years with metastatic lung cancer in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2019. We generated age-adjusted incidence rates (AAIR) and used Joinpoint regression models to estimate the average annual percentage change (AAPC) in incidence across different subgroups. We employed the Joinpoint test of parallelism to identify differences in metastatic lung cancer incidence by sex, race/ethnicity, and residence.
resultsThe incidence of metastatic lung cancer declined more rapidly from 2014 to 2019, compared with 2004 to 2014, in men (AAPC 5.5% (2014 to 2019), 2.3% (2004-2014)) and women (1.7% (2014-2019), 0.86% (2004-2014)), with the test of parallelism indicating narrowing of disparities from 2014 to 2019. Similarly, metastatic lung cancer incidence declined more rapidly from 2014 to 2016 in metropolitan and non-metropolitan residents, with parallel trend lines. However, among racial groups, only White and Black patients had a significant reduction in metastatic lung cancer incidence from 2014 to 2019.
conclusionsOur analysis revealed a significant decline in metastatic lung cancer incidence in most groups since 2014, coinciding with the implementation of LDCT screening. Non-Hispanic American Indian/Alaskan, non-Hispanic Asian/Pacific Islander, and Hispanic patients, however, showed no significant trend change during the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.